Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
ConditionHeart Failure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-85
SponsorBaker Heart and Diabetes Institute
About this trial
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \>50 years old.
The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.
Eligibility criteria
Qualifiers
History of COVID-19 infection
Live within a geographically accessible area for follow-up
Disqualifiers
Valvular stenosis or regurgitation of >moderate severity
History of previous heart failure (baseline New York Heart Association (NYHA) classification >2)
Inability to acquire interpretable images (identified from baseline echo)
Contraindications to beta blockers or angiotensin-converting enzyme inhibitors
Trial design
Treatments tested in this trial
- Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)
- Usual care
Treatment groups
820 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov